Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The St. George's Respiratory Questionnaire as a prognostic factor in IPF.
Furukawa T, Taniguchi H, Ando M, Kondoh Y, Kataoka K, Nishiyama O, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y. Furukawa T, et al. Among authors: ando m. Respir Res. 2017 Jan 17;18(1):18. doi: 10.1186/s12931-017-0503-3. Respir Res. 2017. PMID: 28095852 Free PMC article.
Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y. Shindo Y, et al. Among authors: ando m. Am J Respir Crit Care Med. 2013 Oct 15;188(8):985-95. doi: 10.1164/rccm.201301-0079OC. Am J Respir Crit Care Med. 2013. PMID: 23855620
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Takahashi K, Saito H, Hasegawa Y, Ando M, Yamamoto M, Kojima E, Sugino Y, Kimura T, Nomura F, Ogasawara T, Shindoh J, Yoshida N, Suzuki R. Takahashi K, et al. Among authors: ando m. Cancer Chemother Pharmacol. 2014 Oct;74(4):721-7. doi: 10.1007/s00280-014-2548-z. Epub 2014 Aug 3. Cancer Chemother Pharmacol. 2014. PMID: 25087097 Clinical Trial.
Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System.
Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y. Morise M, et al. Among authors: ando m. Mol Clin Oncol. 2014 Nov;2(6):991-996. doi: 10.3892/mco.2014.354. Epub 2014 Jul 22. Mol Clin Oncol. 2014. PMID: 25279187 Free PMC article.
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Gemma A, et al. Among authors: ando m. Cancer Sci. 2014 Dec;105(12):1584-90. doi: 10.1111/cas.12550. Cancer Sci. 2014. PMID: 25287435 Free PMC article. Clinical Trial.
3,487 results